Prognostic Impact of CCA Components in Combined Hepatocellular Carcinoma-Cholangiocarcinoma

Overview

Journal J Hepatocell Carcinoma

Date 2024 Dec 23

PMID 39712948

Authors

Zhu Zhu

Chun Yang

Mengsu Zeng

Changwu Zhou

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the differences of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) patients with a cholangiocarcinoma (CCA) component ≥ 30% or < 30% versus intrahepatic cholangiocarcinoma (iCCA) patients in recurrence-free survival (RFS) and overall survival (OS) prognoses.

Methods: Patients with cHCC-CCA and iCCA after surgery were recruited. All cHCC-CCA patients were divided into two subgroups (CCA components ≥ 30% and < 30%). Then, Kaplan-Meier survival analysis and Cox regression analysis were used to investigate and compare the differences of cHCC-CCAs with a CCA component ≥ 30% or < 30% versus iCCAs in RFS and OS prognoses, respectively. The differences of MRI features between cHCC-CCAs with a CCA component ≥ 30% and < 30% were also compared.

Results: One hundred sixty-four cHCC-CCAs and 146 iCCAs were enrolled. Compared with iCCAs, cHCC-CCAs with a CCA component < 30% had better OS prognosis (HR: 2.888, p = 0.045). However, Cox regression analysis revealed that cHCC-CCAs with a CCA component ≥ 30% had poorer RFS (HR: 0.503, p < 0.001) and OS (HR: 0.58, p = 0.033) prognoses than iCCAs. In addition, rim APHE (OR = 0.286, p < 0.001), targetoid diffusion restriction (OR = 0.316, p = 0.019), corona enhancement (OR = 0.481, p = 0.033), delayed enhancement (OR = 0.251, p = 0.001), and LR-M (OR = 1.586, p < 0.001) were significant factors associated with cHCC-CCAs with a CCA component ≥ 30%. Multivariable regression analyses showed that only LR-M (OR = 1.522, p = 0.042) was a significantly independent predictor for cHCC-CCAs with a CCA component ≥ 30%.

Conclusion: cHCC-CCAs with a CCA component ≥ 30% had worse prognoses than iCCAs. Therefore, we suggest that the postoperative treatment of cHCC-CCAs with a CCA component ≥ 30% can be based on the treatment strategy for iCCAs.

References

Choi S, Jeon S, Lee S, Lee J, Hur B, Kang H . Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI. Eur Radiol. 2021; 31(12):9479-9488. DOI: 10.1007/s00330-021-07984-w. View

Jeon S, Joo I, Lee D, Lee S, Kang H, Lee K . Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol. 2018; 29(1):373-382. DOI: 10.1007/s00330-018-5605-x. View

Yoon Y, Hwang S, Lee Y, Kim K, Ahn C, Moon D . Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Gastrointest Surg. 2015; 20(2):411-20. DOI: 10.1007/s11605-015-3045-3. View

Jung D, Hwang S, Song G, Ahn C, Moon D, Kim K . Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection. Liver Transpl. 2016; 23(3):330-341. DOI: 10.1002/lt.24711. View

Jiang X, Huang X, Huang C, Chen L, Liang L, Yin X . Long-term outcome and prognostic factors of combined hepatocellular carcinoma and cholangiocarcinoma after curative resection. Gastroenterol Rep (Oxf). 2020; 8(2):134-142. PMC: 7136721. DOI: 10.1093/gastro/goaa003. View

Choi S, Lee S, Park S, Kim K, Yu E, Park Y . LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI. Radiology. 2018; 290(2):388-397. DOI: 10.1148/radiol.2018181290. View

Rossner F, Sinn B, Horst D . Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update. Cancers (Basel). 2023; 15(2). PMC: 9856551. DOI: 10.3390/cancers15020494. View

Zhou C, Wang Y, Ma L, Qian X, Yang C, Zeng M . Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis. Eur Radiol. 2021; 32(1):78-88. DOI: 10.1007/s00330-021-08188-y. View

Beaufrere A, Calderaro J, Paradis V . Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol. 2021; 74(5):1212-1224. DOI: 10.1016/j.jhep.2021.01.035. View

10.

Tang Y, Wang L, Teng F, Zhang T, Zhao Y, Chen Z . The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis. Int J Med Sci. 2021; 18(1):187-198. PMC: 7738961. DOI: 10.7150/ijms.50883. View

11.

Park S, Lee S, Yu E, Kang H, Park Y, Kim S . Combined hepatocellular-cholangiocarcinoma: Gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging. 2016; 46(1):267-280. DOI: 10.1002/jmri.25568. View

12.

Yin X, Zhang B, Qiu S, Ren Z, Zhou J, Chen X . Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol. 2012; 19(9):2869-76. DOI: 10.1245/s10434-012-2328-0. View

13.

He C, Mao Y, Wang J, Song Y, Huang X, Lin X . The Predictive Value of Staging Systems and Inflammation Scores for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgical Resection: a Retrospective Study. J Gastrointest Surg. 2018; 22(7):1239-1250. DOI: 10.1007/s11605-018-3756-3. View

14.

Lin C, Wu T, Lin H, Hung C, Hsieh P, Yeh J . Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis. BMC Gastroenterol. 2021; 21(1):20. PMC: 7788698. DOI: 10.1186/s12876-020-01586-4. View

15.

Lee J, Chung G, Yu S, Hwang S, Kim J, Kim H . Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol. 2010; 45(1):69-75. DOI: 10.1097/MCG.0b013e3181ce5dfa. View

16.

Cao J, Srinivas-Rao S, Mroueh N, Anand R, Kongboonvijit S, Sertic M . Cholangiocarcinoma imaging: from diagnosis to response assessment. Abdom Radiol (NY). 2024; 49(5):1699-1715. DOI: 10.1007/s00261-024-04267-y. View

17.

Bridgewater J, Galle P, Khan S, Llovet J, Park J, Patel T . Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60(6):1268-89. DOI: 10.1016/j.jhep.2014.01.021. View

18.

Chernyak V, Fowler K, Kamaya A, Kielar A, Elsayes K, Bashir M . Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018; 289(3):816-830. PMC: 6677371. DOI: 10.1148/radiol.2018181494. View

19.

Xiao Y, Zheng X, Zhou C, Huang P, Wu F, Yang C . Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction. Eur Radiol. 2022; 33(2):1412-1421. DOI: 10.1007/s00330-022-09131-5. View

20.

Granata V, Fusco R, Setola S, Sandomenico F, Barretta M, Belli A . Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma. Radiol Oncol. 2020; 54(2):149-158. PMC: 7276649. DOI: 10.2478/raon-2020-0029. View